Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02715583 · ClinicalTrials.gov registry record · Early Phase 1
C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer
A Early Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT02715583 is a Early Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 6 participants.
The verdict
NCT02715583, a Early Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Patients with castrate resistant prostate cancer (CRPCA) with osseous metastatic disease planning to undergo Ra-223 therapy may be eligible for this study. Positron emission tomography (PET/CT) imaging will use the investigational radiotracer \[11C\]acetate. Imaging will occur prior to Ra-223 therapy and after 2 cycles, in addition to standard of care 99mTcMDP bone scan at baseline and a research 99mTc-MDP bone scan post-therapy
Interventions
- DRUG 11C-Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-03 |
| Est. Completion | 2020-09-25 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02715583
The ClinicalTrials.gov registry entry for NCT02715583 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 11C-Acetate is the first listed.
NCT02715583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02715583 about?
NCT02715583 is a clinical study titled "C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer". Patients with castrate resistant prostate cancer (CRPCA) with osseous metastatic disease planning to undergo Ra-223 therapy may be eligible for this study. Positron emission tomography (PET/CT) imaging will use the investigational radiotracer \[11C\]acetate. Imaging will occur prior to Ra-223 therap...
What is the current status of trial NCT02715583?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2016-03. Estimated completion is 2020-09-25.
What interventions are being tested in trial NCT02715583?
The interventions under investigation include: 11C-Acetate (DRUG).
Who is sponsoring clinical trial NCT02715583?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.